ATE307606T1 - Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung - Google Patents

Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung

Info

Publication number
ATE307606T1
ATE307606T1 AT01870211T AT01870211T ATE307606T1 AT E307606 T1 ATE307606 T1 AT E307606T1 AT 01870211 T AT01870211 T AT 01870211T AT 01870211 T AT01870211 T AT 01870211T AT E307606 T1 ATE307606 T1 AT E307606T1
Authority
AT
Austria
Prior art keywords
newcastle disease
attenuated mutant
virus
ovo vaccination
vaccine
Prior art date
Application number
AT01870211T
Other languages
English (en)
Inventor
Jan Mast
Guy Meulemans
Original Assignee
Ct Voor Onderzoek In Diergenee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Voor Onderzoek In Diergenee filed Critical Ct Voor Onderzoek In Diergenee
Application granted granted Critical
Publication of ATE307606T1 publication Critical patent/ATE307606T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01870211T 2001-10-04 2001-10-04 Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung ATE307606T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01870211A EP1300157B1 (de) 2001-10-04 2001-10-04 Abgeschwächter Mutantenstamm eines Virus der Newcastle-Krankheit für eine in Ovo Impfung und dessen Benutzung

Publications (1)

Publication Number Publication Date
ATE307606T1 true ATE307606T1 (de) 2005-11-15

Family

ID=8185026

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01870211T ATE307606T1 (de) 2001-10-04 2001-10-04 Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung

Country Status (5)

Country Link
US (1) US7252984B2 (de)
EP (1) EP1300157B1 (de)
AT (1) ATE307606T1 (de)
DE (1) DE60114420T2 (de)
WO (1) WO2003030932A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2508378A1 (en) * 2002-12-02 2004-06-17 University Of Maryland, College Park Avian pneumovirus genes, recombinant avian pneumoviruses and methods of making
US8092808B2 (en) 2003-12-03 2012-01-10 Pfizer, Inc. Ovo vaccination of Campylobacter in avian species
KR20120042865A (ko) * 2006-03-30 2012-05-03 엠브렉스, 인코포레이티드 가금류의 예방접종 방법 및 조성물
CN100487119C (zh) * 2006-05-09 2009-05-13 中国农业科学院哈尔滨兽医研究所 表达禽流感病毒H5亚型HA蛋白的重组新城疫LaSota弱毒疫苗株
EP2085092A1 (de) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Abgeschwächte onkolytische Paramyxoviren zur Kodierung von Vogel-Zytokinen
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
CN102716476B (zh) * 2012-05-31 2015-04-22 郑州后羿制药有限公司 一种细胞灭活疫苗和卵黄抗体注射液及其制备方法
CN102721812B (zh) * 2012-06-20 2014-09-03 江苏省农业科学院 检测嗜肾型鸡传染性支气管炎病毒及其抗体的间接elisa试剂盒
CN105567644A (zh) * 2014-03-13 2016-05-11 华中农业大学 一种抗新城疫病毒单克隆抗体
US20220356476A1 (en) 2019-07-03 2022-11-10 Aim Immunotech Inc. Compositions and methods useful for ebola virus infection
CN110669129B (zh) * 2019-10-31 2022-09-02 江苏省农业科学院 一种新城疫病毒hn蛋白单克隆抗体1g4及其应用
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
CN115161294B (zh) * 2022-06-09 2023-03-21 广东省农业科学院动物卫生研究所 新城疫疫苗株及其构建方法、禽类免疫识别方法、应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693655B1 (fr) * 1992-07-20 1994-10-14 Virbac Vaccin antirabique avirulent.
EP0848956A1 (de) 1996-12-17 1998-06-24 Dimminaco Ag/Sa/Ltd. In ovo Impfung gegen die Newcastle-Krankheit
EP0974660A1 (de) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle-Krankheitsvirus Infektiöser Klone, Impfstoffe und Diagnosetest
KR100760328B1 (ko) * 1999-04-13 2007-10-04 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 클론된 뉴클레오타이드 서열로부터 어테뉴에이티드된네가티브 스트랜드 ｒｎａ 바이러스 백신을 제조하는 방법
EP1074614B1 (de) * 1999-07-27 2004-07-07 Akzo Nobel N.V. Rekombinantes Newcastle-Krankheitsvirus zur in ovo Impfung

Also Published As

Publication number Publication date
EP1300157A1 (de) 2003-04-09
US7252984B2 (en) 2007-08-07
WO2003030932A9 (en) 2003-11-27
WO2003030932A1 (en) 2003-04-17
US20040258713A1 (en) 2004-12-23
DE60114420T2 (de) 2006-07-13
DE60114420D1 (de) 2005-12-01
EP1300157B1 (de) 2005-10-26

Similar Documents

Publication Publication Date Title
ATE307606T1 (de) Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung
DE69937999T2 (de) Interferon induzierende genetisch veränderte attenuierte viren
DE3878468D1 (de) Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
EP2204187A1 (de) Impfstoff gegen menschliche Influenza enthaltend vier Peptide aus Influenza
DE60042114D1 (de) Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.
HUE035395T2 (en) Multivalent recombinant bird herpesviruses and vaccines for immunization of bird species
AR038595A1 (es) Cepas de metaneumovirus y su uso en formulaciones de vacunas y como vectores para la expresion de secuencias antigenicas
DE60035885D1 (de) Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen
Freuling et al. Efficacy of the oral rabies virus vaccine strain SPBN GASGAS in foxes and raccoon dogs
ATE437175T1 (de) Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen
CZ302785B6 (cs) Zpusob prípravy DNA odvozené od koronaviru, príslušné infekcní klony, vektory a vakcíny
CN102099053A (zh) 麻疹-人乳头瘤组合疫苗
JP2004520406A (ja) 弱毒生ワクチン
JP2009529861A (ja) 鳥インフルエンザウイルスのｈ５ヘマグルチニンを発現する組み換えニューキャッスル病ウイルス
JP5432703B2 (ja) 組み換えモノネガウイルス目ウイルスベクター
CA2992158C (en) Duck enteritis virus and the uses thereof
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
WO2021252620A3 (en) Dna encoded antibodies for use against sars-cov-2
CN102458427B (zh) 麻疹-疟疾联合疫苗
BRPI0822947B1 (pt) vacina recombinante.
Ye et al. Error-prone pcr-based mutagenesis strategy for rapidly generating high-yield influenza vaccine candidates
JP2023545524A (ja) 組換えｈｖｔ及びその使用
IL143149A (en) Stable mutants of rabies virus and live vaccines prepared from them
Beckert et al. Genetic stability (in vivo) of the attenuated oral rabies virus vaccine SAD B19

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties